The evolution of the basic science supporting the growth of biotechnology is fascinating, but for me, well understood, from the fundamentals of recombinant DNA technology and taking advantage of basic model organisms to study and manipulate genetic information, to utilizing the biochemical properties of DNA, RNA, polypeptides, and other macromolecules to elucidate the seemingly endless body of biological knowledge - different methods of sequencing including high throughput methods utilizing arrays and fluorophores, as well as supporting technologies such as polymerase chain reaction (PCR) to increase the amount of starting material from even the tiniest number of isolated molecules. What is lesser known to me, as well as a tragic fact of life, is the business side of biotech. The dynamic evolution of the biotech industry overtime, however, is quite fascinating and a delight to learn about, from the fertile grounds for biotech ventures and startups of the early market to the trending ‘urge to merge.’
Genentech is a ripe exemplar of the highly adaptable and productive initial pool of 1st generation biotech companies. Genentech not only developed the novel recombinant DNA technology but also maneuvered through the established world of drug development with expertise, leveraging its new technology into products commanding high value while founding strategic corporate partnerships. The evolution of this market saw the huge successes of IPO’s in the late 1980’s to mid 90’s, and
Biotech companies’ values are primarily driven by intellectual property, they do not need to rely much on their suppliers. These companies also have relatively easy access to sources of raw materials (such as chemicals), scientific tools, computers and testing equipment.
Scientists continue to find new ways to insert genes for specific traits into plant and animal DNA. A field of promise—and a subject of debate—genetic engineering is changing the food we eat and the world we live in.
Imagine eating at a dining establishment and being asked if the ordered main course would preferably be prepared baked, fried, or genetically engineered. Though odd, this question is coming sooner than later. Even though genetic engineering has been around for a long time, due to its increased advances, no longer is it an ignored issue. In fact, it is causing quite a controversy. Some feel, genetic engineering is a scientist 's way of "playing God," creating elements and bodies that were not intended to be on Earth. Possibly, there is some truth to this belief; however, others disagree and see the "act of creating" most beneficial to both science and the economy. Both sides have great claims to their arguments, but after researching
Crichton explains how gene patents were a mistake by the underfinanced and understaffed United States Patent Office which, have halted research and prevented
From a strategic viewpoint, it is my belief that Pills & Co should make a play to purchase Star Genomics for these reasons:
In June 2000, the publicly funded Human Genome Project (HGP) and the private firm Celera Genomics Inc. announced that they had completed sequencing the human genome. This unprecedented accomplishment is expected to enable doctors to diagnose, treat and even prevent numerous genetic diseases. As these two entities worked on sequencing the human genome, there was also a separate and less publicized race to patent as many human genes as possible.
Luke Timmerman is a trained journalist who has worked for quite some time in biotech journalism. He gives a brief history of his life and work history over the years, and his journey to becoming a biotech journalist. He went through some challenges especially writing for different contexts such as business audiences and insiders. He has strived to be a journalist known for the quality of his work rather than the number of clicks. There are tremendous possibilities in the biotech field, writing in this context is promising, Timmerman recounts when he started writing and how he felt privileged working especially with work on cancer. Public engagement is important but not always necessary. Money has a significant role in biotech, especially financing
EXECUTIVE SUMMARYSilicon Valley Medical Technologies (SIVMED) was founded as a research and development firm. In the beginning, SIVMED performed its own basic research, obtained patents on promising technologies, and then either sold or licensed the technologies to other firms which marketed the products. The firm has since then grown and is now contracted to perform research and testing for larger genetic engineering firms, biotechnology firms, the US government, and is now widely recognized as the leader in an emerging growth industry. SIVMED's founders were relatively wealthy individuals when they started company, and they committed a great deal of their own funds to the venture. Their personal funds, however, were soon exhausted by the
Located in South San Francisco, CA, Genentech was started in 1976 by a biochemist Dr. Herbert Boyer and Robert A. Swanson. From 1995-2009 Arthur Levinson had become the CEO of Genentech; presently it is Ian T. Clark. Genentech is a leading biotechnology company, using human genetic information to discover, develop, manufacture and commercialize medicines to treat people with serious or life-threatening medical conditions (2014). Biotechnology is the technology based on the science of cellular and biomolecular processes to develop technologies and products that help improve peoples’ lives and the health of our environment. How biotechnology uses cellular and biomolecular processes are by using molecular mechanisms by which genetic and
The biotech firm Amgen Inc. gives much attention and time to the planning process. Because the outcomes for a company like Amgen are often very unsure and many employees are quite sceptical about the use of such a planning, the main issue can be described as follows:
- The biotech industry is a very uncertain environment top operate in. Giving a quantative planning can create a false sense of accuracy. That way a planning can lose much of it’s added value and confidence in planning might even disappear altogether. Strong points in Amgen’s planning is that the company focuses mainly on qualitative aspects. It should be remarked however that Amgen is in the luxurious situation that because of two very successful products she is not (totally) dependent on external investments.
Early in 1997, Genzyme Corporation began negotiations with Geltex Pharmaceuticals in an attempt to launch a joint venture to market Geltex's first product, RenaGel. Geltex was a young biotech research company with only two products in its pipeline, and they didn't have the resources necessary to launch RenaGel on their own. Genzyme, on the other hand, was a quickly growing company that experienced revenues of $518 million in 1996. They were attracted to the joint venture with Geltex because of the likelihood of increased earnings, as well as the joint venture being an excellent fit for Genzyme's specialty therapeutics. Genzyme also felt that the joint venture would lead to a similar deal in launching Geltex's second product, CholestaGel.
The process of life has always intrigued me. From the abundance of technology being created every day to new cures battling new diseases, the world of biology is continually changing. I have always dreamt of being part of a field whose main purpose is to help others and to improve the world around us; to me that is Biotechnology. Biotechnology is the field for future innovations that benefits an individual, but also the society.
The book From Alchemy to IPO: the business of Biotechnology (2001) was a wonderful read. Although a little outdated (before the 2008 financial crisis), Cynthia Robbins-Roth was able to capture the thrill of starting the first biotech companies, the struggle to keep the companies afloat during down markets, as well as the elation of success when a company succeeds where others failed. I was astounded that any new company could survive the decade long march to putting their first product on the market, but Robbins-Roth provided direct quotations from the major investors that stuck with the market when most other investors had pulled out. These quotes, by the end of the book, gave me a much better understanding not only of the biotech industry but also the mentality of the major investors in the field. Although the sector is teeming with risky investments, if you educate yourself about the companies and understand the science involved, and be ready for the long-haul it is possible to lower your risk to reasonable levels.
Achieve a median composite eight-year product development cycle by 2010. Deliver two new molecular entity (NME) launches on average per year from 2010. In order to achieve the above objective, ensure that we have 10 or more NMEs in Phase III development by 2010. Development cycle times and quality for small molecules and biologics. Number of NME launches per year. Attrition rates. Number of development projects by phase. Number of in-licensing deals, alliances and acquisitions. R&D investment levels. Improving R&D quality and speed through leading-edge science, effective risk management and decision-making and overall business efficiency. Maximising the value of our biologics business and continuing to build a major presence in this fast-growing sector. Investing in external opportunities to enhance our internal innovation through in-licensing, alliances and acquisitions. 2008 target exceeded for small molecule development cycle times. NME and life-cycle management progressions